^
Association details:
| Biomarker: | PRLR underexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | rolinsatamab talirine (ABBV-176) (DNA cross linking agent, Prolactin receptor-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition
Published date:
06/09/2021
Excerpt:
In both in vitro and in vivo assays, ABBV-176 exhibits potent cytotoxicity against multiple cell line and patient-derived xenograft breast tumor models, including triple negative and low PRLR expressing models insensitive to monomethyl auristatin (MMAE) based PRLR ADCs... Collectively the efficacy and safety profile of ABBV-176 suggest it may be an effective therapy across a broad range of breast cancers...
DOI:
10.1186/s12885-021-08403-5
